GlassScriptPhysician profile
Melanie Todd
NPI 1053577106
$2,432.92
in general payments reported to CMS, 2019-2025
23 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $434 · 2023: $791 · 2024: $1,011 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $858.18 | 2022-2025 | |
| Novo Nordisk INC | $357.49 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $187.31 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $116.83 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $116.44 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Verrica Pharmaceuticals INC. | $104.31 | 2024 | Ycanth |
| Dexcom, INC. | $82.50 | 2023-2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $78.09 | 2022 | |
| Exact Sciences Corporation | $64.14 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $62.67 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.83 | 2022 | |
| Amgen INC. | $57.23 | 2023-2024 | Otezla, Repatha, Evenity |
| Eisai INC. | $46.56 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.19 | 2023-2024 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $37.21 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.31 | 2022 | |
| Corium, LLC | $29.17 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $20.53 | 2024 | Auvelity |
| Neos Therapeutics, LP | $19.13 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.30 | 2023 | Quviviq |
| Seqirus USA INC | $13.84 | 2022 | |
| Boston Scientific Corporation | $13.36 | 2023 | |
| Glaxosmithkline, LLC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.